Oxurion NV Business and Financial Update – FY 2020 apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Research reveals link between proteins causing Alzheimer s disease and age-related sight loss
Newly published research has revealed a close link between proteins associated with Alzheimer s disease and age-related sight loss. The findings could open the way to new treatments for patients with deteriorating vision and through this study, the scientists believe they could reduce the need for using animals in future research into blinding conditions.
Amyloid beta (AB) proteins are the primary driver of Alzheimer s disease but also begin to collect in the retina as people get older. Donor eyes from patients who suffered from age-related macular degeneration (AMD), the most common cause of blindness amongst adults in the UK, have been shown to contain high levels of AB in their retinas.
Sponsored Story
By StoryStudio February 18, 2021 12:04 pm
(BPT) – Age-Related Macular Degeneration (AMD) Month serves as an important reminder for people to stay on top of their eye health. AMD is one of the most common causes of vision loss later in life, affecting millions of Americans.
We talked to Dr. David Eichenbaum, an ophthalmologist at Retina Vitreous Associates of Florida in Tampa, FL, about what people should know about AMD and ways people can preserve their vision.
Nice to meet you, Dr. Eichenbaum. First off, can you tell us more about what AMD is?
Definitely, thank you for having me here to talk about this very important and timely subject. AMD is a disease that impacts the retina the part of the eye that gives you sharp, central vision and it’s a leading cause of blindness in people 60 and over.
Scientists find new therapeutic approach to effectively treat age-related macular degeneration
Runt-related transcription factor 1 (RUNX1) has been linked to retinal neovascularization and the development of abnormal blood vessels, which result in vision loss in diabetic retinopathy. Now, scientists have found that RUNX1 inhibition presents a new therapeutic approach in the treatment of age-related macular degeneration (AMD), which is the leading cause of blindness in the elderly worldwide. Their results are reported in
The American Journal of Pathology, published by Elsevier.
Abnormal growth of blood vessels, or aberrant angiogenesis, arises from the choroid, a part of the eye located behind the retina. This condition, known as choroidal neovascularization (CNV), is present in several ocular diseases that lead to blindness such as AMD. This study is the first to implicate RUNX1 in CNV and to test RUNX1 inhibition therapy for treating CNV. Researchers found that application of a
New ophthalmology service launched in Naas
Reporter:
23 Feb 2021
Photo L-R: Siobhan Zinn-Collis, Affidea Naas, Dr Magdy Nastralla Abdall, Vicki Cummins, Vista Eye Clinic, and Nidhi Gupta, Affidea Naas. );
);
Affidea, Ireland’s leading independent provider of diagnostic imaging and outpatient services, held its first Age-related Macular Degeneration AMD injection clinic in its JCI accredited Clinic in Naas this week.
Affidea are working with Vista Eye Clinic in the running of this outpatient service.
These clinics are been run by Consultant Ophthalmologist, Dr Magdy Nastralla Abdall, who has a keen interest in retinal diseases such as AMD and Diabetic Retinopathy.